- Home
- TS vs RPRX Comparison
TS vs RPRX Comparison
Compare TS & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TS
- RPRX
- Stock Information
- Founded
- TS 2001
- RPRX 1996
- Country
- TS Luxembourg
- RPRX United States
- Employees
- TS N/A
- RPRX N/A
- Industry
- TS Steel/Iron Ore
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- TS Industrials
- RPRX Health Care
- Exchange
- TS Nasdaq
- RPRX Nasdaq
- Market Cap
- TS 18.4B
- RPRX 16.2B
- IPO Year
- TS N/A
- RPRX 2020
- Fundamental
- Price
- TS $40.68
- RPRX $40.88
- Analyst Decision
- TS Buy
- RPRX Strong Buy
- Analyst Count
- TS 5
- RPRX 3
- Target Price
- TS $41.80
- RPRX $46.00
- AVG Volume (30 Days)
- TS 1.6M
- RPRX 2.9M
- Earning Date
- TS 10-29-2025
- RPRX 11-05-2025
- Dividend Yield
- TS 4.18%
- RPRX 2.16%
- EPS Growth
- TS N/A
- RPRX N/A
- EPS
- TS 1.86
- RPRX 1.60
- Revenue
- TS $11,831,250,000.00
- RPRX $2,349,553,000.00
- Revenue This Year
- TS N/A
- RPRX $36.16
- Revenue Next Year
- TS $0.80
- RPRX $2.04
- P/E Ratio
- TS $10.46
- RPRX $25.42
- Revenue Growth
- TS N/A
- RPRX 3.69
- 52 Week Low
- TS $30.06
- RPRX $24.05
- 52 Week High
- TS $40.89
- RPRX $41.24
- Technical
- Relative Strength Index (RSI)
- TS 69.74
- RPRX 75.93
- Support Level
- TS $39.56
- RPRX $36.03
- Resistance Level
- TS $40.89
- RPRX $37.40
- Average True Range (ATR)
- TS 0.72
- RPRX 1.11
- MACD
- TS 0.47
- RPRX 0.38
- Stochastic Oscillator
- TS 96.88
- RPRX 93.15
About TS Tenaris S.A.
Tenaris is one of the largest global producers of oil country tubular goods, which are used primarily in the construction of oil and gas wells. Its production facilities are located primarily in the US, Argentina, Mexico, and Italy. Tenaris' premium OCTG products are among the most trusted by oil companies for use in the most challenging applications, including deep-water offshore wells and horizontal shale wells.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.